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Insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs) have been implicated in the aetiology of
several cancers. To better understandwhether anthropometric, behavioural and sociodemographic factorsmay play a role in cancer
risk via IGF signalling, we examined the cross-sectional associations of these exposures with circulating concentrations of IGFs (IGF-I
and IGF-II) and IGFBPs (IGFBP-1, IGFBP-2 and IGFBP-3). The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer
Collaborative Group dataset includes individual participant data from 16,024male controls (i.e. without prostate cancer) aged
22–89 years from 22 prospective studies. Geometric means of protein concentrations were estimated using analysis of variance,
adjusted for relevant covariates. Older age was associatedwith higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations
of IGF-I, IGF-II and IGFBP-3. Higher bodymass index was associatedwith lower concentrations of IGFBP-1 and IGFBP-2. Taller height was
associated with higher concentrations of IGF-I and IGFBP-3 and lower concentrations of IGFBP-1. Smokers had higher concentrations of
IGFBP-1 and IGFBP-2 and lower concentrations of IGFBP-3 than nonsmokers. Higher alcohol consumption was associatedwith higher
concentrations of IGF-II and lower concentrations of IGF-I and IGFBP-2. African Americans had lower concentrations of IGF-II, IGFBP-1,
IGFBP-2 and IGFBP-3 and Hispanics had lower IGF-I, IGF-II and IGFBP-3 than non-Hispanic whites. These findings indicate that a range of
anthropometric, behavioural and sociodemographic factors are associated with circulating concentrations of IGFs and IGFBPs inmen,
which will lead to a greater understanding of themechanisms throughwhich these factors influence cancer risk.
What’s new?
In many cancers, evidence points to insulin-like growth factors and their associated binding proteins as a possible culprit. This
study investigated how IGF and IGF binding proteins correlate with various other cancer-associated factors. The authors
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obtained data from 16,000 cancer-free males ranging in age from 22 to 89 years. Their analysis confirmed associations
between circulating IGFs and IGFBPs and age, race/ethnicity and BMI. They also uncovered some new associations, including
with height, drinking alcohol and smoking. IGFs and their binding proteins, they suggest, may be part of the mechanism by
which these factors influence cancer risk.
Introduction
Insulin-like growth factors (IGFs) and their associated binding
proteins (IGFBPs) are fundamental mediators of cell growth,
development and survival and are expressed in most tissues.1,2
Epidemiological evidence implicates IGFs and IGFBPs in risk for
prostate, breast, colorectal cancer3–5 and possibly thyroid cancer;6
in particular, IGF-I is consistently positively associated with an
increased risk of these cancers.3–6 Circulating concentrations of
IGFs and IGFBPs may be modified by a range of anthropometric,
behavioural and sociodemographic factors,7,8 many of which are
also implicated in cancer aetiology.9–13 By identifying the corre-
lates of circulating concentrations of IGFs and IGFBPs, we may
better understand whether IGFs provide a plausible biological
mechanism through which lifestyle and behavioural factors are
associated with cancer risk. Although some previous research has
investigated potential associations with circulating IGF-I and
IGFBP-3,14–16 relatively few studies have investigated the corre-
lates of IGF-II, IGFBP-1 and IGFBP-2 concentrations.14,17
The Endogenous Hormones, Nutritional Biomarkers and
Prostate Cancer Collaborative Group (EHNBPCCG) was
established to conduct pooled analyses of circulating concen-
trations of endogenous hormones and other biomarkers in
relation to prostate cancer risk. Using unified methods, this
large individual-level participant dataset is well placed to describe,
with high precision, the potential anthropometric, behavioural
and sociodemographic determinants of IGFs and IGFBPs both
at extremes of their association, and with substantial statistical
power to identify novel associations.
Materials and Methods
Data collection
Principal investigators were invited to join the EHNBPCCG if
they had published or unpublished data on prostate cancer risk
and endogenous hormone concentrations and/or nutritional
biomarkers from blood samples collected from men prior to
diagnosis of prostate cancer and male controls. These were
identified using literature search methods and personal contact
as described previously.18–20 Collaborators provided data on
baseline IGF and IGFBP concentrations and a range of expo-
sures: anthropometric (including height, weight, waist circum-
ference and waist-to-hip ratio [WHR]), behavioural (smoking
and alcohol) and sociodemographic factors (racial/ethnic group,
education status), generally collected at the same time as blood
collection (Supporting Information Tables S1, S2a and S2b).
The data from each study were collected and incorporated into
a central database.
Men were considered eligible for this analysis if they had
measures of at least one of circulating IGF-I, IGF-II, IGFBP-1,
IGFBP-2 or IGFBP-3 concentrations, were not known to have
been diagnosed with prostate cancer by the time of individual
study closure, and age, height and weight were recorded at the
time of blood collection. Overall, 16,024 men (out of 17,838;
Supporting Information Fig. S1) from 22 studies were included
in the analyses. As this analysis used secondary data, ethical
approval was not necessary; however, each study individually
obtained ethical approval and further details of participant con-
sent and study design can be found in the original publications.
Further details of data collection and included studies are
found in the Supporting Information Methods.
Statistical analysis
IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations
were logarithmically transformed to approximate normal distribu-
tions. The analyses examined associations with age (22–49 [mean
age = 42.6], 50–54, 55–59, 60–64, 65–69, 70–74, 75+ years),
body mass index (BMI [<20.0, 20.0–22.4, 22.5–24.9, 25.0–27.4,
27.5–29.9, 30.0–32.4, 32.5–34.9, 35.0–37.4, 37.5+ kg/m2]), height
(<160.0, 160.0–164.9, 165.0–169.9, 170.0–174.9, 175.0–179.9,
180.0–184.9, 185.0–189.9, 190.0+ cm), smoking status (never, ex
and current: <15, 15–29, 30+ cigarettes per day), alcohol consump-
tion (none, 1–9, 10–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70+ g
ethanol per day), ethnic/racial group (non-Hispanic white, African
American/Caribbean, Hispanic/Latino, East Asian and other), waist
circumference (<90.0, 90.0–94.9, 95.0–99.9, 100.0–104.9, 105.0+ cm)
and WHR (<0.900, 0.900–0.932, 0.933–0.966, 0.967–0.999, 1.00+),
marital status (currently married/cohabiting, not currently
married/cohabiting) and family history of prostate cancer (no, yes:
defined as a father and/or brother diagnosed with prostate cancer)
with circulating IGF and IGFBP concentrations. Categories of the
exposure variables investigated were defined a priori based on
sample size and the data distribution.
Partial correlations between the IGFs and IGFBPs were cal-
culated using study-specific standardised values: (xjk − mj)/sj,
where mj and sj denote the mean and standard deviation of
the log-transformed IGF concentrations in study j and xjk is
an observation from that study, enabling comparison across
studies. These correlation coefficients were adjusted for age at
blood collection, BMI and height (included as categorical vari-
ables, described above).
Geometric mean concentrations of IGFs and IGFBPs were
calculated using predicted values from analysis of variance
models scaled to the overall geometric mean concentration
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and adjusted for study, age at blood collection, BMI and height
(except for the analyses of age, BMI and height with IGF and
IGFBP concentrations, where the exposure variable was not
included as an adjustment covariate). Adjusted geometric mean
concentrations in relation to waist circumference andWHR were
also repeated with and without adjustment for BMI. Analyses of
smoking and alcohol consumption were mutually adjusted for
each other. To enable robust adjustment for study, each study
had to contain observations in a minimum of two categories for
each primary exposure to be included in the respective exposure
analysis. To investigate the relationship of IGF and IGFBP con-
centrations with ethnicity/race, the analyses were limited to the
five (all USA-based) studies that had sufficient representation
from men across several ethnic/racial groups (see Supporting
Information Methods).
Heterogeneity of means by category of each characteristic
was tested using the F test. Where appropriate, a test for trend
was calculated using the analysis of variance test, with the cate-
gorical variables entered as linear values scored consecutively as
1, 2, 3 etc. Owing to the highly skewed distribution of alcohol
consumption, the test for trend was calculated based on median
values within each category excluding nondrinkers. To test for
trend by smoking status, never and former smokers were com-
bined and coded as 0; light, medium and heavy smokers were
coded as 1, 2 and 3, respectively, as current smoking status may
be more likely to determine circulating IGF and IGFBP concen-
trations than previous smoking history. In a secondary analysis,
the test for trend was calculated for current smokers only.
Heterogeneity between studies was tested using a study-by-
factor interaction term (fitted separately) in the analysis of vari-
ance and assessed using the F test. Circulating IGFBP-1 and
IGFBP-2 concentrations are known to be affected by food
intake.21,22 As fasting status was not recorded for 58% of partici-
pants, this variable was not included as a covariate in the ana-
lyses, but heterogeneity between exposure factors and overnight
fasting status for these two binding proteins was assessed using
the likelihood ratio test.
Sensitivity analyses were conducted after restricting the
dataset to: (i) white men only (n = 11,611), (ii) studies which
used enzyme-linked immunosorbent assays (ELISA), (iii) men
with IGF and IGFBP concentrations that were within the range
of [lower quartile – 3 * interquartile range, upper quartile +3 *
interquartile range] within each study in order to examine the
effect of outliers (n = 147). The primary analysis was also
repeated after further adjustment for smoking and alcohol.
All statistical tests were two-sided, and owing to a large num-
ber of tests conducted, the statistical significance threshold was
set at p < 0.01. Data analysis was carried out using Stata Statisti-
cal Software release 14.1 (Stata Corp., College Station, TX).
Results
Twenty-two studies including 16,024 participants contributed
data to the analysis (Supporting Information Table S1). Blood
was collected 1959–2009, and age at blood collection ranged
from 22 to 89 years (mean = 61.2; SD = 9.5 years). Partici-
pants were predominantly non-Hispanic white (90%), non-
smokers (83%) and 81% reported consuming some alcohol
(median per day = 10 g ethanol, approximately equal to one
standard alcoholic beverage).
Correlations between protein concentrations
After standardising for study and adjusting for age, BMI and
height, all IGFs and IGFBPs were correlated with each other.
IGF-I was positively correlated with both IGFBP-3 and IGF-II
(r = 0.58 and 0.41, respectively) and weakly inversely correlated
with IGFBP-1 and IGFBP-2 (r = −0.15 and −0.09, respectively).
IGF-II was positively correlated with IGFBP-3 (r = 0.65) and
inversely correlated with IGFBP-1 and IGFBP-2 (r = −0.20 and
−0.11, respectively; Supporting Information Table S3).
Age at blood collection
After adjusting for study, BMI and height, age was associated
with all IGFs and IGFBPs (Fig. 1). Compared to men aged
50–54 years, those aged 75+ years had circulating concentra-
tions of IGFBP-2 and IGFBP -1 that were 73 and 61% higher,
respectively, while IGF-I, IGFBP-3 and IGF-II concentrations
were 24, 21 and 19% lower, respectively.
Adiposity
After adjusting for study, age and height, BMI was associated
with IGF and IGFBP concentrations (Fig. 2). Compared to men
with a BMI of 20.0–22.4 kg/m2, those with a BMI ≥ 37.5 kg/m2
had concentrations of IGFBP-1 and IGFBP-2 that were 77 and
58% lower, respectively. IGF-I, IGF-II and IGFBP-3 had inverse
U-shaped associations with BMI.
The patterns of associations were broadly similar for waist cir-
cumference and WHR (Supporting Information Figs. 2 and 3),
although there was no significant association between WHR and
IGF-I or IGFBP-3. Compared to men with waist circumference
90–94 cm, those with waist circumference ≥105 cm had circu-
lating concentrations of IGFBP-1 and IGFBP-2 that were 43 and
37% lower, respectively (Supporting Information Fig. 2). After
additional adjustment for BMI, IGFBP-1 and IGFBP-2 concentra-
tions were 19 and 14% lower, respectively in men with waist cir-
cumference ≥105 cm. Compared to men with WHR 0.900–0.932,
those with WHR ≥ 1.00 had circulating concentrations of IGFBP-1
and IGFBP-2 that were 34 and 30% lower, respectively (Supporting
Information Fig. 3). After additional adjustment for BMI, IGFBP-1
and IGFBP-2 concentrations were 11 and 10% lower, respectively,
in men with WHR ≥ 1.00.
Height
After adjusting for study, age and BMI, height was associated
with concentrations of IGF-I and IGFBP-1 and IGFBP-3
(Fig. 3). Compared to shorter men (160–164 cm), the tallest
men (≥190 cm) had concentrations of IGFBP-1 that were
35% lower, while IGF-I and IGFBP-3 concentrations were
7 and 3% higher, respectively.
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Smoking
After adjusting for study, age, BMI, height and alcohol con-
sumption, smoking status was associated with IGFBP concentra-
tions (Fig. 4). Compared to never smokers, heavy smokers (30+
cigarettes/day) had concentrations of IGFBP-1 and IGFBP-2
that were 39 and 20% higher, respectively, while heavy smokers
had 4% lower concentrations of IGFBP-3. However, the associa-
tion between smoking intensity and circulating IGFBPs was not
statistically significant when the analyses were restricted to cur-
rent smokers only (p > 0.01, data not shown).
Figure 1. Relative geometric mean concentrations* of male IGFs and IGFBPs by age. p for heterogeneity is the heterogeneity of means
between categories, tested using the F test. p for trend was calculated using the analysis of variance test, with categorical variables entered
as linear values scored consecutively. *Relative to 50–54 years, adjusted for study, BMI and height. #Significant heterogeneity by study
p < 0.01. Abbreviations: IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein.
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Alcohol
After adjusting for study, age, BMI, height and smoking status,
alcohol consumption was associated with IGFs and IGFBP-2
(Fig. 5). Compared to men who drank 1–9 g ethanol/day, men
who drank ≥70 g ethanol/day had circulating concentrations of
IGF-II that were 5% higher, while IGF-I and IGFBP-2 concen-
trations were 13 and 7% lower, respectively.
Nondrinkers had 5, 4 and 2% lower concentrations of IGF-
II, IGFBP-3 and IGF-I, respectively, than men who drank
1–9 g ethanol per day.
Figure 2. Relative geometric mean concentrations* of male IGFs and IGFBPs by BMI. p for heterogeneity is the heterogeneity of means
between categories, tested using the F test. p for trend was calculated using the analysis of variance test, with categorical variables entered
as linear values scored consecutively. *Relative to BMI 20.0–22.4 kg/m2, adjusted for study, age and height. #Significant heterogeneity by
study p < 0.01. Abbreviations: IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein.
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Ethnic/racial group
After adjusting for study, age, BMI and height, racial/ethnic
group was associated with all IGF and IGFBP concentrations
(Fig. 6). Compared to non-Hispanic white men, African Ameri-
can men had concentrations of IGFBP-1, IGFBP-2, IGF-II and
IGFBP-3 that were 36, 33, 11 and 6% lower, respectively. His-
panics had concentrations of IGFBP-2, IGF-I, IGFBP-3 and
IGF-II that were 15, 13, 12 and 9% lower, respectively. Concen-
trations of IGFs and IGFBPs for East Asian men were similar
to non-Hispanic white men.
Figure 3. Relative geometric mean concentrations* of male IGFs and IGFBPs by height. p for heterogeneity is the heterogeneity of means
between categories, tested using the F test. p for trend was calculated using the analysis of variance test, with categorical variables entered
as linear values scored consecutively. *Relative to 175.0–179.9 cm, adjusted for study, age and BMI. #Significant heterogeneity by study
p < 0.01. Abbreviations: IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein.
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Sociodemographic factors and health
After adjusting for study, age, BMI and height, men who were
married or cohabiting at the time of blood collection had 4%
higher concentrations of IGF-I and IGF-II compared to men
who were not married at blood collection (Supporting Infor-
mation Fig. S4). Family history of prostate cancer was not
associated with IGF or IGFBP concentrations (Supporting
Information Fig. S5).
Figure 4. Relative geometric mean concentrations* of male IGFs and IGFBPs by smoking status. p for heterogeneity is the heterogeneity of
means between categories, tested using the F test. p for trend was calculated using the analysis of variance test, with categorical variables
entered as linear values scored consecutively. Never and ex-smokers were combined into a single category. *Relative to never smokers,
adjusted for study, age, BMI, height and alcohol consumption. #Significant heterogeneity by study p < 0.01. Abbreviations: IGF, insulin-like
growth factor; IGFBP, insulin-like growth factor-binding protein.
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Heterogeneity and sensitivity analysis
Some heterogeneity was observed between studies in the asso-
ciations of IGF and IGFBP concentrations with anthropomet-
ric and sociodemographic factors. When the associations were
assessed separately for each study the direction was the same;
the heterogeneity was due to differences in the magnitudes of
associations (data not shown).
Similarly, significant heterogeneity was observed across
studies in the associations between age and IGFBP-1, and
BMI and IGFBP-2 by fasting status. Again, this heterogeneity
Figure 5. Relative geometricmean concentrations* ofmale IGFs and IGFBPsby alcohol consumption.p for heterogeneity is the heterogeneity ofmeans
between categories, tested using the F test.p for trendwas calculated using the analysis of variance test, with categorical variables entered as linear values
scored as themedian valuewithin each category and excludednondrinkers. *Relative to 1–9 g ethanol/day, adjusted for study, age, height, BMI and
smoking status. #Significant heterogeneity by study p < 0.01. Abbreviations: IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein.
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appeared to be due to differences in the magnitudes of the
associations (Supporting Information Figs. S6 and S7).
The results remained broadly similar after restricting the dataset
to non-Hispanic white men, ELISA only assays, excluding outlier
values for IGF and IGFBP concentrations, and after further adjust-
ment of all analyses for smoking and alcohol (data not shown).
Discussion
This analysis of individual participant data from 22 studies
confirms strong associations of age, anthropometric factors
and racial/ethnic groups with circulating IGFs and their bind-
ing proteins, and shows some novel associations, particularly
with height, smoking and alcohol consumption. The large size
Figure 6. Relative geometric mean concentrations* of male IGFs and IGFBPs by ethnic/racial group. p for heterogeneity is the heterogeneity of means
between categories, tested using the F test. *Relative to non-Hispanic whites, adjusted for study, age, height and BMI. #Significant heterogeneity by
study p < 0.01. Abbreviations: Af Am/Cab, African American/Caribbean; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein.
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and inclusion of different populations enabled us to assess
these associations across a wider range of exposure distribu-
tions than has previously been possible.
Our results showed that age is associated with circulating
concentrations of all IGFs and binding proteins. IGF-I, IGF-II
and IGFBP-3 concentrations were lower in older men, which
has previously been reported.23 We also found that IGFBP-1
and IGFBP-2 concentrations were higher in older men, which
might be related to reduced insulin sensitivity24,25 and beta-
cell function.26
We found that BMI had modest inverse U-shaped associa-
tions with IGF-I, IGF-II and IGFBP-3. Low energy consump-
tion is associated with lower circulating IGF-I concentrations,27
therefore increasing energy consumption may explain the mod-
erate associated increase in IGF-I concentrations in men with
BMI < 20.0 kg/m2 through to BMI 25.0–27.5 kg/m2. Above this
BMI, higher adiposity may impair liver function, reducing IGF-I
secretion.28 BMI also had strong inverse associations with
IGFBP-1 and IGFBP-2, which may largely be driven by high
insulin concentrations.29–31 Changes in circulating IGFBP-1
concentrations may affect IGF-I bioavailability,32,33 increasing
the risk of neoplastic transformation;34,35 consequently, a reduc-
tion in IGFBP-1 may partly explain why BMI may influence
the risk of cancers which are associated with circulating IGF
concentrations (prostate, colorectal, breast and thyroid).9,13,36
After additional adjustment for BMI, both waist circumfer-
ence and WHR remained significantly inversely associated
with IGFBP-1 and IGFBP-2. This suggests that central adipos-
ity may also be an important independent predictor of these
concentrations.
IGF-I plays a fundamental role in the regulation of growth
in height.37 In our analyses, height had modest positive associ-
ations with IGF-I and IGFBP-3, and a marked inverse associa-
tion with IGFBP-1. Prospective studies consistently indicate
that greater height is associated with an increased risk of pros-
tate (aggressive forms), colorectal and breast cancer,13,38 and
it is possible that increased IGF-I bioavailability, which may
be influenced by IGFBP-1,32,33 may account for part of these
associations.
Smoking status was associated with differing circulating con-
centrations of IGFBPs. The inverse association between
smoking and IGFBP-3 in men has been reported previously,
although this association has not been observed in women.39,40
To the best of our knowledge, previous studies have not found
an association between smoking and IGFBP-1 and IGFBP-
2,41,42 but they did not stratify by sex. Our findings, however,
did not show evidence of a linear trend when we tested the
association excluding nonsmokers. Although smoking increases
the risk of many cancers,9,10 the small magnitudes of the associ-
ations with IGFBPs that we report here imply that changes in
these concentrations due to smoking are unlikely to contribute
to these large increases in cancer risk.
Alcohol consumption was inversely associated with IGF-I
and IGFBP-2 concentrations and positively associated with
IGF-II. Alcohol affects the liver by impaired insulin receptor
binding and increased oxidative stress due to the toxicity of
ethanol,43 which may in turn cause changes in IGF synthesis
by the liver. We are unaware of any previous studies which
have found an association between alcohol and IGF-II or
IGFBP-2, although in mice hepatic IGF-II has been shown to
increase after liver injury as part of the repair process.44 Alco-
hol consumption is associated with short-term decreases in
IGF-I and increases in IGFBP-1 concentrations, but concen-
trations normalise after alcohol metabolism;45 no data were
available in our dataset regarding the men’s time or quantity
of last drink. Alcohol consumption increases the risk of sev-
eral cancers, including breast and colorectal cancer;9 our
results indicate that alcohol may also affect cancer risk via
IGF-related pathways.
Five studies had adequate representation of men across dif-
ferent racial/ethnic groups, all from the US. Hispanics and
African American men had lower IGF-II, IGFBP-1, IGFBP-2
and IGFBP-3 concentrations compared to non-Hispanic
whites. Hispanics also had lower IGF-I concentrations than
white men,46 whereas concentrations of IGF-I in African
Americans were similar to those in whites. Overall, Hispanics
have a lower incidence of cancers associated with circulating
IGF concentrations, in comparison with non-Hispanic whites,
while African Americans have an increased incidence of pros-
tate cancer.11,12 In Hispanics, the reduction in both IGF-I and
IGFBPs may reduce the concentration of bioavailable IGF-I,
whereas the lower concentrations of IGFBPs in African Amer-
icans might lead to an increase in bioavailable IGF-I. These
differences may contribute to cancer risk between racial/ethnic
groups.
For several associations, there was heterogeneity between
the included studies. This was generally due to differences in
the magnitudes of associations, rather than the direction. Het-
erogeneity may have been due to differences in sample
populations, study design and assays. The majority of studies
used ELISA assays, although exact methods varied, which may
contribute to some of the observed differences in magnitudes
of associations.47,48
This analysis has a number of strengths. The large size of
the dataset enabled us to assess these associations across a
wider range of exposure distributions than previously possible,
particularly for IGF-II and IGFBP-1 and IGFBP-2, which have
been the focus of less research. Our analysis also accounts for
differences between studies to enable comparisons of the mag-
nitudes of the associations relative to the different IGFs and
their binding proteins.
The analysis also has some limitations. The data are cross-
sectional and therefore it is not possible to infer whether the
observed associations are causal. Our analysis is also based on
single measurements, on the assumption that these measures
are representative of participants’ hormone concentrations
over the medium-to-long term. Studies suggest that IGF-I has
acceptable temporal reproducibility over 1- to 5-year period
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(intraclass correlation coefficient 0.70–0.75),16,49 fewer data
are available for IGF-II, IGFBP-1 and IGFBP-2. In this
dataset, no data were available for some other potential deter-
minants or confounders such as physical activity,50 diet,14,51
comorbidities (such as diabetes and kidney or liver disease) or
treatment for these diseases,52,53 which might also influence
cancer risk via IGFs.54,55 Fasting status was missing for 58%
of IGFBP-1 and IGFBP-2 data.
In conclusion, our large collaborative analysis indicates
that age, BMI, height and ethnic/racial group are strongly
associated with circulating IGF and IGFBP concentrations,
while smoking status and alcohol consumption have more
modest associations. IGFs and IGFBPs might therefore
account for some of the observed association of BMI, height
and race/ethnicity and risk of IGF-related cancers. These find-
ings improve our understanding of the mechanisms through
which these factors influence cancer risk.
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